A new drug, ErSO-TFPy, has shown promising results in eliminating breast tumors in mice after a single dose. This breakthrough offers hope for a less invasive and more effective treatment for ER+ breast cancer, potentially reducing the need for long-term hormone therapy and its associated side effects.
Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone therapy, but late effects of these treatments include osteoporosis, sexual dysfunction, and blood clots. Now, researchers reporting in ACS Central Science have created a novel treatment that eliminated small breast tumors and significantly shrank large tumors in mice in a single dose, without problematic side effects.
Most breast cancers are estrogen receptor positive (ER+), and treatment typically involves several years of hormone therapy. Although these drugs are better tolerated than chemotherapy, they still have side effects that diminish quality of life and can leave people at risk for cancer recurrence and treatment resistance. Thus, there is a need for cancer drugs that kill tumor cells selectively and aggressively, while limiting side effects. To address this challenge, Paul Hergenrother and colleagues previously developed a small molecule called ErSO. This compound kills ER+ breast cancer cells but results in undesirable side effects. In 2022, the researchers synthesized a series of small molecules similar to ErSO. That prior study demonstrated that these derivatives have higher potency, greater selectivity for ER+ cancer cells, and better pharmacological properties than the original compound. Now, in the latest study, the researchers further evaluated one derivative, ErSO-TFPy, and found that it: Related Stories In a dosing experiment, the researchers noted that a single dose of ErSO-TFPy in mice induced complete or near-complete regression of small or large tumors, respectively, that had grown in the animals. Other drugs require long-term dosing, but the researchers suggest that a lone dose of ErSO-TFPy and therefore minimal circulation in the body could help reduce the risk of side effects and late effects. They acknowledge the need for more testing to confirm drug safety and efficacy, but they suggest if these results translate to human patients, ErSO-TFPy could be transformative for ER+ breast cancer treatment. It is very rare for a compound to shrink tumors in mouse models of breast cancer, let alone completely eradicate those tumors with a single dose, so we are eager for ErSO-TFPy to advance for treatment of breast cancer. ' Paul Hergenrother Source:American Chemical Society Journal reference:Mulligan, M. P. et al. (2025) Single Dose of a Small Molecule Leads to Complete Regressions of Large Breast Tumors in Mice. ACS Central Science. doi.org/10.1021/acscentsci.4c01628
BREAST CANCER DRUG DEVELOPMENT ONCOLOGY ER+ BREAST CANCER TUMOR TREATMENT
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Single-dose malaria vaccine offers unprecedented 90% protectionResults from the malaria vaccine trial indicate that GA2 immunization provides significant protection, paving the way for more effective vaccination strategies.
Read more »
New Year's Eve Rain and Chilly New Year in Store for New EnglandNew Year's Eve will be dry with mild temperatures until midnight when showers begin and last through New Year's Day. A colder air mass moves in Wednesday bringing snow to northern New England. Strong winds expected Thursday combined with snow could cause power outages and damage. Lake-effect and ocean effect snow possible northwest and off the coast, but much of New England will see a dry, sunny, and chilly weekend. A potential storm next week could bring rain and snow to southern New England.
Read more »
New Governor, New Challenges for New Hampshire RepublicansNew Hampshire's incoming governor faces a host of pressing issues, including housing affordability, homelessness, and a challenging budget cycle. Simultaneously, the state GOP is undergoing a leadership change, raising questions about the party's direction and future prospects.
Read more »
Christine McGuinness on Single Life and New RomanceChristine McGuinness opens up about life after separation from Paddy McGuinness, sharing how she and Paddy are navigating co-parenting while living together. She also discusses her newfound happiness with a new partner and her focus on self-confidence.
Read more »
Every single person named in the New Year's Honours list 2025Every year a number of people are handed honours by the King
Read more »
New nanopore-based tool enables single molecule disease detectionUC Riverside scientists have developed a nanopore-based tool that could help diagnose illnesses much faster and with greater precision than current tests allow, by capturing signals from individual molecules.
Read more »